- Home
- NEXM vs SERA Comparison
NEXM vs SERA Comparison
Compare NEXM & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEXM | SERA |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Canada | United States |
| Employees | 204 | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.7M | 75.2M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEXM | SERA |
|---|---|---|
| Price | $2.33 | $2.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 35.5K | 21.6K |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1044.00 | 32.32 |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | $3.67 | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $2.03 | $1.56 |
| 52 Week High | $6.65 | $3.95 |
Technical Indicators
Market Signals| Indicator | NEXM | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 50.12 |
| Support Level | $2.29 | $1.79 |
| Resistance Level | $2.38 | $2.07 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 28.33 | 47.25 |
Price Performance
Historical ComparisonAbout NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.